Targacept, Inc. 200 East First Street, Suite 300 Winston-Salem, NC 27101-4165 Therapeutic Focus:  Nervous system diseases and disorders Therapeutic Targets:  Neuronal nicotinic receptors (NNRs), which are key regulators of the nervous system Product Candidates:  TC-5619, negative symptoms and cognitive dysfunction in schizophrenia, inattentive-predominant ADHD and potentially Alzheimer's disease; AZD3480, Alzheimer's disease; AZD1446, Alzheimer's disease; and TC-6987 for inflammatory disorders.

President & CEO:  J. Donald deBethizy, Ph.D. Number of Employees:  75                                    Date Established:  March 1997 IPO Completed:  April 2006 NASDAQ Ticker Symbol:  TRGT

Strategic Alliances:

Global collaboration and license agreement with AstraZeneca AB for AZD3480 and AZD1446 for the treatment of Alzheimer's disease or other cognitive disorders. 

 Intellectual Property:  Pentad^TM, a proprietary drug discovery platform; and an extensive patent estate covering compounds that act on NNRs

Founders:

• J. Donald deBethizy, Ph.D., President & Chief Executive Officer
• Merouane Bencherif, M.D., Ph.D., Senior Vice President, Preclinical Research
• William S. Caldwell, Ph.D., Senior Vice President, Drug Discovery and Development
• Patrick M. Lippiello, Ph.D., Senior Principal Scientist